Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

8.725
-0.240-2.68%
Volume:62.00K
Turnover:548.82K
Market Cap:8.45B
PE:-72.71
High:9.265
Open:9.250
Low:8.700
Close:8.965
52wk High:15.750
52wk Low:6.230
Shares:968.00M
HK Float Shares:968.00M
Volume Ratio:0.43
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.120
ROE:-6.43%
ROA:-4.42%
PB:4.23
PE(LYR):-72.71
PS:12.79

Loading ...

Alphamab Oncology publishes 2025 annual report

Reuters
·
Apr 28

HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%

Tiger Newspress
·
Apr 28

ALPHAMAB-B Grants 250,000 Award Shares to Two Employees

Stock News
·
Apr 23

Alphamab Oncology grants 250,000 restricted share awards to employees under incentive scheme

Reuters
·
Apr 23

HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%

Tiger Newspress
·
Apr 23

ALPHAMAB-B Secures Three-Year HKEX Waiver to Appoint Jiang Rui as Joint Company Secretary

Bulletin Express
·
Apr 22

ALPHAMAB-B's KN026 Breast Cancer Trial Results Selected for Oral Presentation at 2026 ASCO Annual Meeting

Stock News
·
Apr 22

Alphamab Oncology: KN026 Phase III Neoadjuvant Breast-Cancer Results Chosen for 2026 ASCO Late-Breaking Oral Session

Bulletin Express
·
Apr 22

Alphamab Oncology says KN026 Phase III neoadjuvant breast cancer results selected for ASCO LBA oral session

Reuters
·
Apr 22

ALPHAMAB-B Shares Surge Over 12% in Morning Session as KN026 Commercialization Nears

Stock News
·
Apr 13

ALPHAMAB-B Announces Appointment of Jiang Rui as Joint Company Secretary

Stock News
·
Apr 08

Alphamab Oncology names Jiang Rui joint company secretary, authorized representative

Reuters
·
Apr 08

Alphamab Oncology Keeps Share Base Steady at 974.29 Million Shares in March; Confirms 25%+ Public Float

Bulletin Express
·
Apr 08

Assessing Alphamab Oncology (SEHK:9966) Valuation After A Mixed Period Of Share Price Returns

Simply Wall St.
·
Apr 07

CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint

MT Newswires Live
·
Apr 01

Stock Track | ALPHAMAB-B Soars 5.13% Intraday After Phase III Breast Cancer Trial Meets Primary Endpoint

Stock Track
·
Apr 01

Alphamab Oncology says Phase III KN026 neoadjuvant HER2+ breast cancer trial meets primary endpoint

Reuters
·
Apr 01

BRIEF-Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint

Reuters
·
Mar 31

ALPHAMAB-B (09966): Phase III Trial of KN026 as Neoadjuvant Therapy for HER2-Positive Breast Cancer Meets Primary Endpoint

Stock News
·
Mar 31

Alphamab Oncology - Phase Iii Study of Kn026 With Hb1801 for Her2+ Bc Met Primary Endpoint

THOMSON REUTERS
·
Mar 31